Altimmune Total Current Assets from 2010 to 2024
| ALT Stock | USD 6.55 0.15 2.34% |
Total Current Assets | First Reported 2005-06-30 | Previous Quarter 153 M | Current Value 209.5 M | Quarterly Volatility 73.3 M |
Check Altimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altimmune main balance sheet or income statement drivers, such as Interest Expense of 33.2 K, Selling General Administrative of 13.5 M or Total Revenue of 404.7 K, as well as many exotic indicators such as Price To Sales Ratio of 1.5 K, Dividend Yield of 0.0 or PTB Ratio of 3.24. Altimmune financial statements analysis is a perfect complement when working with Altimmune Valuation or Volatility modules.
Altimmune | Total Current Assets |
Latest Altimmune's Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Altimmune over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Altimmune's Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Altimmune's overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Altimmune Total Current Assets Regression Statistics
| Arithmetic Mean | 102,769,294 | |
| Geometric Mean | 59,710,725 | |
| Coefficient Of Variation | 92.08 | |
| Mean Deviation | 88,317,158 | |
| Median | 39,394,749 | |
| Standard Deviation | 94,627,178 | |
| Sample Variance | 8954.3T | |
| Range | 215.9M | |
| R-Value | 0.73 | |
| Mean Square Error | 4545.5T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 15,384,209 | |
| Total Sum of Squares | 125360.2T |
Altimmune Total Current Assets History
About Altimmune Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Altimmune income statement, its balance sheet, and the statement of cash flows. Altimmune investors use historical funamental indicators, such as Altimmune's Total Current Assets, to determine how well the company is positioned to perform in the future. Although Altimmune investors may use each financial statement separately, they are all related. The changes in Altimmune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Altimmune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Altimmune Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Altimmune. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 209.5 M | 220 M |
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving together with Altimmune Stock
| 0.71 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.7 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.67 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Altimmune Stock
| 0.7 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.59 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.41 | HCM | HUTCHMED DRC | PairCorr |
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Altimmune Correlation against competitors. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.